ATS 2019 Virtual Final Program

P529 Effect of Protocol-Driven Observation Unit Admissions on 30-Day Readmissions for Acute Exacerbations of Chronic Obstructive Pulmonary Disease/ J. Bell, D. Steiger, N. Bhogal, P.S. Patrawalla, New York, NY, p.A3340 P530 To Compare the Efficacy and Safety of Nebulized Short Acting Beta Agonists/Short Acting Muscarinic Agents (SABA/SAMA) with and Without the Addition of Inhaled LABA/LAMA in Hospitalized COPD Patients/ G. Thommi, J.C. Shehan, P.G. Meyers, Omaha, NE, p.A3341 P531 Benefits of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) in Symptomatic Patients with COPD: A Post-Hoc Analysis from a Phase III, Randomized, Placebo-Controlled Study (PINNACLE-4)/ B.J. Lipworth, D.J. Collier, G.J. Feldman, S. Arora, M. Jenkins, C. Reisner, U.J. Martin, Dundee, United Kingdom, p.A3342 P532 Performance of Contemporary Portable Oxygen Concentrators Across Diverse Breathing Behaviours/ D.C. Martin, T. Cheng, M. Su, R. Bertinato, Baulkham Hills, Australia, p.A3343 P533 The Analysis of Non-Invasive Positive Pressure Ventilation in Treating COPD Patients Accompanied with Chronic Respiratory Failure/ T. Ma, Y. Hu, B. Yan, Changchun, China, p.A3344 P534 Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Improves Lung Function in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies/ F.J. Martinez, K.F. Rabe, B.J. Lipworth, S. Arora, M. Jenkins, A. Maes, U.J. Martin, C. Reisner, New York, NY, p.A3345 P535 Improved Perception of Mucus Clearance and Benefit After Nasal High Flow Therapy in Women with COPD and Asthma/ J. Given, R. Troyer, L. Girard, M. Ferrall, Canton, OH, p.A3346 P536 The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings/ M.C. Kaisermann, G.J. Criner, M.T. Dransfield, D.M. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, F.J. Martinez, S.J. Pascoe, D. Singh, R.A. Wise, D.A. Lipson, Collegeville, PA, p.A3347 P537 Does Inhaler Continuity and Familiarity Provide Clinical Benefits for Management of Patients with Chronic Obstructive Pulmonary Disease or Asthma?/ R. Dhand, A. Hickey, D. Guranlioglu, K. Rawson, N. Stjepanovic, S. Siddiqui, O.S. Usmani, Knoxville, TN, p.A3348 P538 Domiciliary Noninvasive Positive Pressure Ventilation Prolongs Time to Death in Patients with Chronic Obstructive Pulmonary Disease/ H.C. Kulkarni, S. Patel, S. Parthasarathy, Tucson, AZ, p.A3349 P539 Effects of Inhaler Therapy on Mortality in Patients with Tuberculous Destroyed Lung and Airflow Limitation/ H. Kim, T.H. Kim, C.K. Rhee, M. Han, Y.-M. Oh, Seoul, Korea, Republic of, p.A3350 P540 12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-Suspension Delivery Technology in Patients with COPD/ G.T. Ferguson, K.F. Rabe, E. Bourne, S. Ballal, K. DeAngelis, M. Aurivillius, C. Reisner, P. Dorinsky, Farmington Hills, MI, p.A3351 P541 Noninvasive Mechanical Ventilation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Combined with Elevated B-Type Natriuretic Peptide (BNP)/ J. Su, R. Zhang, K. Cheng, Shanghai, China, p.A3352 P542 Prescription Tendencies and Clinical Outcomes of ICS for Management of COPD, A ‘Real World’ Review/ G. Rampon, M. Reddy, S. Burke, L. Bushmann, S. Patolia, E. Charbek, St. Louis, MO, p.A3353 P543 Comparison of Differential Effects of Inhaled Symbicort and Advair on Lung Microbiome - Preliminary Results from the DiSARM Trial/ F.S.S. Leitao Filho, J.-Y. Moon, H. Takiguchi, Y. Sun, K. Akata, S.F. Van Eeden, T. Shaipanich, S. Lam, J. Leung, D.D. Sin, Vancouver, Canada, p.A3354 CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION B46 IDIOPATHIC INTERSTITIAL PNEUMONIA: NATURAL HISTORY 9:15 a.m. - 4:15 p.m. KBHCCD Area B (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : L.P. Hariri, BS, MD, PhD, Boston, MA P169 Tumor-Associated Markers in Idiopathic Pulmonary Fibrosis: Associations with Pulmonary Functions and Smoking Index/ Y. Peng, L. Song, T. Guo, C. Nayra, M. Rojas, S. Ren, R. Ouyang, P. Chen, P. Hong, Changsha, China, p.A3355 P170 The Management and Outcomes of Patients with Both Interstitial Lung Disease and Lung Cancer/ K.F. Flack, S. Chu, C. Ciunci, A. Berman, M. Kreider, M. Porteous, Philadelphia, PA, p.A3356 P171 The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis/ D. Weng, H. Li, Shanghai, China, p.A3357 P172 Analysis of the Clinical Characteristics of 176 Patients with Pathologically Confirmed Cryptogenic Organizing Pneumonia/ D. Weng, Y. Zhang, H. Li, Shanghai, China, p.A3358 P173 Assessment of Circulating Mitochondrial DNA as a Liquid Biomarker in Acute Exacerbation of Idiopathic Pulmonary Fibrosis/ K. Sakamoto, T. Furukawa, Y. Yamano, R. Teramachi, K. Kataoka, N. Hashimoto, Y. Kondoh, Y. Hasegawa, Nagoya, Japan, p.A3359 P174 Non-Acidic Reflux Correlates with Disease Severity in Idiopathic Pulmonary Fibrosis/ Y. Wakwaya, D. Ramadurai, J. King, A. Babaei, J.J. Swigris, Denver, CO, p.A3360 ATS 2019 • Dallas, TX MONDAY • MAY 20 163 MONDAY MORNING